Alkermes oncology spinout Mural charts its future

Mural Oncology’s separation from Alkermes this week will create a discrete, pure-play biotech with a potential pipeline-in-a-product as its centerpiece.

The launch of Mural Oncology plc (NASDAQ:MURA) will leave behind the revenue-generating CNS drugs of Alkermes plc (NASDAQ:ALKS), as well as its neuroscience pipeline. CEO Caroline Loew told BioCentury that “classic tensions” between two therapeutic areas with different investment profiles had resulted in a “robbing Peter to pay Paul” scenario, resulting in the decision to split in two...